The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO Italy 2022 | Promising immunotherapeutic agents under investigation in AML: sabatolimab and magrolimab
Alessandro Isidori, MD, PhD, Marche Nord Hospital, Pesaro, Italy, discusses current immunotherapeutic agents under investigation for the treatment of acute myeloid leukemia (AML), drawing focus on sabatolimab and magrolimab. Dr Isidori first explains the mechanism of action of sabatolimab, and highlights promising clinical trial data that has been observed with the use of this agent. Following this, Dr Isidori discusses the promising role of magrolimab in patients with TP53-mutated disease, and ongoing trials in this space. This interview took place at The 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
